Biomarkers and translational research and precision medicine

43P - CIP2A as a novel target to combat basal like breast cancer

Authors
  • Srikar Nagelli (Turku, Finland)
  • Anni Laine (Amsterdam, Netherlands)
  • Tomi Suomi (Turku, Finland)
  • Laura Elo (Turku, Finland)
  • Jukka Westermarck (Turku, Finland)
Speakers
  • Srikar Nagelli (Turku, Finland)

Previous ePoster
42P_PR - Painting the global picture of HER2-testing for breast cancer. The ONCOLLEGE-001 survey study

Next ePosters
46P - BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience
49P - The metastatic potential of grade I breast carcinoma of no special type: A deep insight into putative molecular mechanisms
50P - ER pathway activity score as a predictive biomarker to improve stratification for neoadjuvant endocrine therapy
51P - Higher ER load is not associated with better outcome in stage I-III breast cancer
52P - The early changes of ΔSUV is a predictive marker of response and outcome in everolimus treated patients with mBC
53P - Activity of chemotherapy drugs in patient-derived xenografts (PDXs) from chemotherapy naïve local-regional triple negative breast cancer (LR-TNBC) patients
54P - Prognostic and predictive value of phosphorylated HER2, HER3 and PTEN expression in patients with HER2-positive breast cancer treated with trastuzumab
55P - Tryptophan catabolism differentiates breast cancer patients from healthy controls but does not predict outcome
58P - Spindle cell carcinoma of the breast: Rare cancer with potentially targetable biomarkers
59P - Myeloid derived-suppressor cells in healthy women and in advanced breast cancer patients